{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:44Z","timestamp":1792718324985,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we describe 3 randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn\u2019s disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 or 6\u00a0mg (LATTICE-CD), 6\u00a0mg (LATTICE-UC), or 12\u00a0mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at week 12. The primary endpoint was clinical remission (per modified Mayo score) at week 12 for LATTICE-UC and clinical response (per modified Mayo score) at week 12 for IM011-127.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all 3 studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn\u2019s disease or ulcerative colitis. Deucravacitinib was safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf080","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:58:33Z","timestamp":1746259113000},"source":"Crossref","is-referenced-by-count":17,"title":["Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert","family":"D\u2019Haens","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Inflammatory Bowel Disease Clinic , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago Medicine , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]},{"name":"Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9 - Hartmann, Paris IBD Center , Neuilly sur Seine ,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Toho University Sakura Medical Center , Sakura, Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Kitasato University Kitasato Institute Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Elsharkawi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Miceli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Napoli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Dornic","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2026072303511557600_CIT0001","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med."},{"key":"2026072303511557600_CIT0002","doi-asserted-by":"crossref","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"2026072303511557600_CIT0003","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2026072303511557600_CIT0004","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2026072303511557600_CIT0005","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1007\/s12325-023-02605-y","article-title":"Unmet needs in real-world advanced therapy-na\u00efve and -experienced patients with moderately to severely active ulcerative colitis in the United States","volume":"40","author":"Afzali","year":"2023","journal-title":"Adv Ther."},{"key":"2026072303511557600_CIT0006","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med."},{"key":"2026072303511557600_CIT0007","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026072303511557600_CIT0008","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ibd.20475","article-title":"IL-23\/IL-17 immunity as a hallmark of Crohn\u2019s disease","volume":"14","author":"H\u00f6ltt\u00e4","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"2026072303511557600_CIT0009","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J Exp Med."},{"key":"2026072303511557600_CIT0010","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: one cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur J Immunol."},{"key":"2026072303511557600_CIT0011","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2026072303511557600_CIT0012","volume-title":"Skyrizi [package insert].","year":"2024"},{"key":"2026072303511557600_CIT0013","volume-title":"Stelara [package insert].","year":"2024"},{"key":"2026072303511557600_CIT0014","doi-asserted-by":"crossref","first-page":"ii42","DOI":"10.1093\/ecco-jcc\/jjac038","article-title":"IL-23 monoclonal antibodies for IBD: so many, so different","volume":"16","author":"McDonald","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2026072303511557600_CIT0015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.4049\/jimmunol.181.3.2071","article-title":"TYK2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells","volume":"181","author":"Nakamura","year":"2008","journal-title":"J Immunol."},{"key":"2026072303511557600_CIT0016","doi-asserted-by":"crossref","first-page":"11594","DOI":"10.1073\/pnas.1930781100","article-title":"A natural mutation in the TYK2 pseudokinase domain underlies altered susceptibility of B10.Q\/J mice to infection and autoimmunity","volume":"100","author":"Shaw","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026072303511557600_CIT0017","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the treatment of psoriatic disease","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am J Clin Dermatol."},{"key":"2026072303511557600_CIT0018","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ecco-jcc\/jjaa199","article-title":"Tyrosine kinase 2 signalling drives pathogenic T cells in colitis","volume":"15","author":"De Vries","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2026072303511557600_CIT0019","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","article-title":"Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology."},{"key":"2026072303511557600_CIT0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"2026072303511557600_CIT0021","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"2026072303511557600_CIT0022","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2026072303511557600_CIT0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"2026072303511557600_CIT0024","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol."},{"key":"2026072303511557600_CIT0025","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med."},{"key":"2026072303511557600_CIT0026","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem."},{"key":"2026072303511557600_CIT0027"},{"key":"2026072303511557600_CIT0028","first-page":"6","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2026072303511557600_CIT0029"},{"key":"2026072303511557600_CIT0030"},{"key":"2026072303511557600_CIT0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"2026072303511557600_CIT0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci."},{"key":"2026072303511557600_CIT0033","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med."},{"key":"2026072303511557600_CIT0034","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"2026072303511557600_CIT0035","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf080\/63158639\/jjaf080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf080\/63158639\/jjaf080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf080\/63158639\/jjaf080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:51:26Z","timestamp":1784793086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf080\/8129055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf080","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,13]]},"article-number":"jjaf080"}}